PDT | Jotup

Draganfly to Host Shareholder Update and Q3 Earnings Call

Retrieved on:

Monday, November 6, 2023

Los Angeles, CA., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, announced today that it will host a shareholder update call on November 9, 2023, at 2:30 PDT / 5:30 p.m. EDT.

Key Points:

Los Angeles, CA., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, announced today that it will host a shareholder update call on November 9, 2023, at 2:30 PDT / 5:30 p.m. EDT.
The shareholder update call will be facilitated by Draganfly CEO Cameron Chell, who will review the Company’s milestones, and CFO Paul Sun, who will review the Company’s financial results for Q3 2023, which are planned to be filed after-market on November 9, 2023.
Draganfly Lead Director Scott Larson will facilitate pre-submitted and live chat questions and answers.
The Company will answer pre-submitted questions of prepared remarks.

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Retrieved on:

Friday, November 3, 2023

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.

Key Points:

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.
I look forward to evaluating the trial results as they continue to mature and remain highly encouraged by the observations to date.
Two patients at the 2mg/kg dose, one with gastric cancer and one with ovarian cancer have demonstrated reduction in tumor burden.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on:

Wednesday, November 1, 2023

PD-L1, PDT, Vaccine, Carcinoma, Head, PD-1, Doctor of Philosophy, Cell, Poster, SITC, Cancer, Immunotherapy, Society for Immunotherapy of Cancer, Lung cancer, Tumor microenvironment, Society, IDO, TME

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, today announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC) being held in San Diego, California from November 1-5, 2023.

Key Points:

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, today announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC) being held in San Diego, California from November 1-5, 2023.
“The data presented provide clear evidence that our immune modulating vaccines, developed based on our T-win technology platform, impact several immune escape mechanisms as elegantly exemplified in abstract #1468,” said Mai-Britt Zocca, PhD, President and Chief Executive Officer of IO Biotech.
“The data in this poster demonstrate enhanced in vivo anti-tumor effect when IDO and PD-L1 vaccines are co-administered in these models, further supporting the clinical observations regarding our lead investigational therapeutic vaccine candidate, IO102-IO103, which targets IDO and PD-L1.
Our T-Win technology vaccine candidates are designed to kill both tumor cells and immune suppressive cells in the TME, by stimulating activation of T cells against a particular target, such as arginase-1.

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on:

Tuesday, October 31, 2023

Gene editing, CAR, PDT, San Diego Convention Center, Cell, SITC, Immunotherapy, Euronext Growth, Neoplasm, TGFBR2, Safety, Society, Doctor of Philosophy, Vaccine, Cellectis

The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.

Key Points:

The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
“We demonstrate that combination of the ΔPD1-IL12 with TGFBR2 KO not only enhanced CAR-T cell activity but surprisingly limit their accumulation outside the tumor, therefore reducing the risks of off-tumor toxicity.
These cells also show strong anti-tumor activity against distal tumors when infused intratumorally”, said Laurent Poirot, Ph.D., SVP Immunology at Cellectis.
These pre-clinical data highlight the capability of multi-armored allogeneic CAR T-cells to preserve their activity despite the immunosuppressive microenvironment, while mitigating potential safety concerns.

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

Retrieved on:

Tuesday, October 31, 2023

PDT, Progression-free survival, Society for Immunotherapy of Cancer, Hope, EST, Poster, SITC, Immunotherapy, Clinical trial, Infection, Society, Patient, Pharmaceutical industry

A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023.

Key Points:

A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023.
Today’s update underscores its promise in immuno-oncology, with our EVX-01 vaccine safely eliciting robust immune responses in all patients.
Notably, a pronounced tumor reduction in a metastatic patient with initial progressive disease following EVX-01 treatment offers hope for those with life-threatening cancer.
Earlier this year, Evaxion reported a successful Phase 1 clinical trial for EVX-01 in combination with a checkpoint inhibitor.

AGM and Management Presentation Details

Retrieved on:

Monday, October 30, 2023

ASX, CDI, PDT, Meeting, Novo, NVO, St Georges Terrace, AWST, TSX

VANCOUVER, British Columbia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to provide further details of the Company’s upcoming annual general meeting (the “Meeting”), scheduled for 6:00 p.m. PDT on Tuesday, 31 October 2023, and of the management presentation to be given immediately after the Meeting.

Key Points:

VANCOUVER, British Columbia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to provide further details of the Company’s upcoming annual general meeting (the “Meeting”), scheduled for 6:00 p.m. PDT on Tuesday, 31 October 2023, and of the management presentation to be given immediately after the Meeting.
Please see the Company’s notice of meeting and information circular, as filed under the Company’s profile at www.sedarplus.ca and released on the Company’s website (at www.novoresources.com ) and on the ASX platform (at https://www.asx.com.au/markets/company/nvo ), for details of the Meeting and how to participate electronically.
CDI holders in Australia can view the Meeting proceedings and the subsequent management presentation from 9:00am AWST 1 November 2023 by attending the offices of Johnson Winter Slattery, Level 49, Central Park, 152 – 158, St Georges Terrace, Perth WA 6000.
Tuesday October 31 6:30 p.m. PDT
- if you are not a registered shareholder, please use the ‘view as guest’ link
*Please note that you may be required to download Zoom software prior to joining the management presentation.

ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023

Retrieved on:

Friday, November 3, 2023

ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).

Key Points:

ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).
“We are thrilled to present proof-of-concept data from our novel sesutecan ADC platform with the initial clinical results for Rina-S,” said ProfoundBio Chief Medical Officer Naomi Hunder, M.D.
Enrolled patients had the following tumor types: ovarian cancer (n=17), endometrial cancer (n=9), breast cancer (n=3), non-small cell lung cancer (n=5), and mesothelioma (n=2).
Superior tumor growth inhibition and tolerability relative to the precedent PTK7-directed ADC cofetuzumab pelidotin were observed in head-to-head preclinical studies.

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on:

Thursday, November 2, 2023

Oncology, Health, Clinical Trials, Research, Science, Biotechnology, ASH, Pharmacodynamics, ACET, Patient, Cancer, PDT, Bio, American Society for Investigative Pathology, Society, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.

Key Points:

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.
Details of the poster presentation are as follows:
Title: Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
Session Name: 704.
Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT

Carvana Announces Record Third Quarter Results for Total Gross Profit per Unit, Net Income, and Adjusted EBITDA

Retrieved on:

Thursday, November 2, 2023

“For the second consecutive quarter, we delivered GPUs that far exceed our 2021 high water marks and generated hundreds of millions of positive net income and Adjusted EBITDA despite a challenging industry environment.

Key Points:

“For the second consecutive quarter, we delivered GPUs that far exceed our 2021 high water marks and generated hundreds of millions of positive net income and Adjusted EBITDA despite a challenging industry environment.
Looking toward 2024, Carvana expects to drive significant Total GPU and Adjusted EBITDA1 for the second consecutive year.
Carvana will host a conference call today, November 2, 2023, at 5:30 p.m. EDT (2:30 p.m. PDT) to discuss financial results.
Total gross profit per retail unit, non-GAAP is Gross profit, non-GAAP divided by retail vehicle unit sales.

Intevac Announces Third Quarter 2023 Financial Results

Retrieved on:

Wednesday, November 1, 2023

Technology, Hardware, Other Technology, Data Management, Lean, Intevac, Investment, GAAP, PDT, Accounting, EDT, Internet, HDD, Bank

A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release.

Key Points:

A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release.
Non-GAAP net income for the third quarter of 2023 was $0.1 million, or $0.00 per diluted share, compared to a non-GAAP net loss of $3.2 million, or $0.13 per diluted share, in the third quarter of 2022.
A reconciliation of the GAAP and non-GAAP results is provided in the financial tables included in this release.
Management uses non-GAAP results to evaluate the Company’s operating and financial performance in light of business objectives and for planning purposes.